Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 10;S0091-6749(20)30634-5.
doi: 10.1016/j.jaci.2020.05.002. Online ahead of print.

Safety and Efficacy of Early High-Dose IV Anakinra in Severe COVID-19 Lung Disease

Affiliations
Free PMC article

Safety and Efficacy of Early High-Dose IV Anakinra in Severe COVID-19 Lung Disease

Emanuele Pontali et al. J Allergy Clin Immunol. .
Free PMC article

Abstract

Cytokine release syndrome plays a crucial pathogenic role in COVID-19 pneumonia. This pilot study provides the first evidence of the safety of anti-IL-1 treatment with highdose IV anakinra in 5 patients, who experienced a positive outcome.

Keywords: COVID-19; anakinra; cytokine release syndrome; interleukin-1; pneumonia.

Similar articles

See all similar articles
Feedback